The patient was treated with prednisolone (5–10 mg/day) and human IgG1 monoclonal antibody specific for tumor necrosis factor-α (TNF-α, adalimumab) at a dose of 40 mg once every two weeks, which was introduced 2 years ago to treat arthritis and reduce the adverse effects of steroids. This evidence concerns the gene TNF and arthritic joint disease.